Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas: A Multicenter Study (STORM)
International Journal of Radiation Oncology*Biology*Physics · 2024-11 · 120 (3) · 730-737
DOI: 10.1016/j.ijrobp.2024.04.016 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-11. Verfasst von Matthew Gallitto und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian, New York, New York. Hauptthemen laut MEDLINE: Meningioma, Radiosurgery, Salvage Therapy, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The role of stereotactic radiosurgery (SRS) in the management of grade 2 and 3 meningiomas is not well elucidated. Unfortunately, local recurrence rates are high, and guidelines for management of recurrent disease are lacking. To address this knowledge gap, we conducted STORM (Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas), a multicenter retrospective cohort study of patients treated with primary SRS for recurrent grade 2 and 3 meningiomas. METHODS AND MATERIALS: Data on patients with recurrent grade 2 and 3 meningioma treated with SRS at first recurrence were retrospectively collected from 8 academic centers in the United States. Patients with multiple lesions at the time of initial diagnosis or more than 2 lesions at the time of first recurrence were excluded from this analysis. Patient demographics and treatment parameters were extracted at time of diagnosis, first recurrence, and second recurrence. Oncologic outcomes, including progression-free survival (PFS) and overall survival, as well as toxicity outcomes, were reported at the patient level. RESULTS: From 2000 to 2022, 108 patients were identified (94% grade 2, 6.0% grade 3). A total of 106 patients (98%) had upfront surgical resection (60% gross-total resection) with 18% receiving adjuvant radiation therapy (RT). Median time to first progression was 2.5 years (IQR, 1.34-4.30). At first recurrence, patients were treated with single or fractionated SRS to a median marginal dose of 16 Gy to a maximum of 2 lesions (87% received single-fraction SRS). The median follow-up time after SRS was 2.6 years. The 1-, 2-, and 3-year PFS was 90%, 75%, and 57%, respectively, after treatment with SRS. The 1-, 2-, and 3-year overall survival was 97%, 94%, and 92%, respectively. In the multivariable analysis, grade 3 disease (HR, 6.80; 95% CI, 1.61-28.6), male gender (HR, 3.48; 95% CI, 1.47-8.26), and receipt of prior RT (HR, 2.69; 95% CI, 1.23-5.86) were associated with worse PFS. SRS dose and tumor volume were not correlated with progression. Treatment was well tolerated, with a 3.0% incidence of grade 2+ radiation necrosis. CONCLUSIONS: This is the largest multicenter study to evaluate salvage SRS in recurrent grade 2 and 3 meningiomas. In this select cohort of patients with primarily grade 2 meningioma with a potentially more favorable natural history of delayed, localized first recurrence amenable to salvage SRS, local control rates and toxicity profiles were favorable, warranting further prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian, New York, New York.
- Department of Neurological Surgery and Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio.
- Department of Radiation Oncology, Alexander T. Augusta Military Medical Center, Fort Belvoir, Virginia.
- Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- The James Comprehensive Cancer Center at The Ohio State University Wexner Medical Center, Columbus, Ohio.
Zitieren
APA
Gallitto, M., Sedor, G., Lee, A., Pasetsky, J., Kinslow, C. J., Santos, G. L., Obiri-Yeboah, D., Kshettry, V. R., Helis, C. A., Chan, M. D., Beckham, T. H., McGovern, S. L., Matsui, J., Palmer, J. D., Bell, J. B., Mellon, E. A., Lakomy, D., Huang, J., Boor, I., …, & Wang, T. J. C. (2024). Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas: A Multicenter Study (STORM). International Journal of Radiation Oncology*Biology*Physics, 120(3), 730-737. https://doi.org/10.1016/j.ijrobp.2024.04.016
Vancouver
Gallitto M, Sedor G, Lee A, Pasetsky J, Kinslow CJ, Santos GL, et al. Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas: A Multicenter Study (STORM). International Journal of Radiation Oncology*Biology*Physics. 2024;120(3):730-737. doi:10.1016/j.ijrobp.2024.04.016
BibTeX
@article{Gallitto2024,
author = {Gallitto, Matthew and Sedor, Geoffrey and Lee, Albert and Pasetsky, Jared and Kinslow, Connor J and Santos, Genesis De Los and Obiri-Yeboah, Derrick and Kshettry, Varun R and Helis, Corbin A and Chan, Michael D and Beckham, Thomas H and McGovern, Susan L and Matsui, Jennifer and Palmer, Joshua D and Bell, Jonathan B and Mellon, Eric A and Lakomy, David and Huang, Jiayi and Boor, Ian and Rusthoven, Chad G and Sisti, Michael B and Wang, Tony J C},
title = {Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas: A Multicenter Study (STORM)},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
volume = {120},
number = {3},
pages = {730--737},
doi = {10.1016/j.ijrobp.2024.04.016}
}
EUVIMED